SpringerProtocols: Abstract: Novel Tools for Production and Purification of Recombinant Adeno-Associated Viral Vectors

Novel Tools for Production and Purification of Recombinant Adeno-Associated Viral Vectors

By: Julian D. Harris², Stuart G. Beattie², J. George Dickson²

Abstract

Full Text

Download PDF (249K)

Original standard protocols for the generation of recombinant adeno-associated viruses (rAAVs) have generally involved the cotransfection of 293 cells with a rAAV plasmid vector (pAAV) and a helper/packaging plasmid, followed by over-infection with a helper virus, normally an adenovirus (Ad) at low multiplicity of infection (MOI) (1). The pAAV vector contains the transgene of interest flanked by the AAV inverted terminal repeats (ITRs) and the helper/packaging plasmid contains the rep and cap genes of wild-type AAV. The drawback with this procedure is the presence of contaminating Ad helper, together with wild-type-like AAV particles in the derived virus vector stocks. This is because of recombination between the rAAV plasmid and rep and cap genes on the packaging plasmid resulting in the restoration of a wild-type virus. In addition, Ad infection can result in lysis of more than 50% of cells prematurely, releasing rAAV particles into the supernatant and therefore reducing virus particle yields from cellular extracts (2).

Affiliation(s): (2) Division of Biochemistry, School of Biological Sciences, Royal Holloway University of London, UK

Book Title: Viral Vectors for Gene Therapy: Methods and Protocols

Series: Methods in Molecular Medicine | Volume: 76 | Pub. Date: Oct-07-2002 | Page Range: 255-267 | DOI: 10.1385/1-59259-304-6:255

Subject: Genetics/Genomics

References

Download References

1.	Samulski, R. J., Chang, L.-S., and Shenk, T. (1989) Helper-free stocks of recombinant adeno-associated viruses: Normal integration does not require viral gene expression. J. Virol. 63, 3822–3828.

2.	Grimm, D., Kern, A., Rittner, K., and Kleinschmidt, J. A. (1998) Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum. Gene Ther. 9, 2745–2760.

3.	DuBridge, R. B., Tang, P., Hsia, H. C., Leong, P. M., Miller, J. H., and Calos, M. P. (1987) Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol. Cell. Biol. 7, 379–387.

4.	Li, J., Samulski, R. J., and Xiao, X. (1997) Role for highly regulated rep gene expression in adeno-associated virus vector production. J. Virol. 71, 5236–5243.

5.	Wistuba, A., Kern, A., Weger, S., Grimm, D., and Kleinschmidt, J. A. (1997) Subcellular compartmentalization of adeno-associated virus type 2 assembly. J. Virol. 71, 1341–1352.

6.	Weger, S., Wistuba, A., Grimm, D., and Kleinschmidt, J. A. (1997) Control of adeno-associated virus type 2 cap gene expression: Relative influence of helper virus, terminal repeats, and Rep proteins. J. Virol. 71, 8437–8447.

7.	Vincent, A., Piraino, S. T., and Wadsworth, S. C. (1997) Analysis of recombinant adeno-associated virus packaging and requirements for rep and cap gene products. J. Virol. 71, 1897–1905.

8.	Allen, J. M., Debelak, D. J., Reynolds, T. C., and Miller, A. D. (1997) Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by nonhomologous recombination curing AAV vector production. J. Virol. 71, 6816–6822.

9.	Dong, J.-Y., Fan, P.-D., and Frizzell, R. A. (1996) Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum. Gene Ther. 7, 2101–2112.

10.	Grimm, D. and Kleinschmidt, J. A. (1999) Progress in adeno-associated virus type 2 vector production: Promises and prospects for clinical use. Hum. Gene Ther. 10, 2445–2450.

11.	Zolotukhin, S., Byrne, B. J., Mason, E., Zolotukhin, I., Potter, M., Chesnut, K., et al. (1999) Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6, 973–985.

12.	Summerford, C. and Samulski, R. J. (1998) Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72, 1438–1445.

13.	Snyder, R.O., Xiao, X., and Samulski, R. J. (1996) Production of recombinant adeno-associated viral vectors, in Current Protocols in Human Genetics (Draco-poli N., et al., eds.), Wiley, New York, pp. 12.1.11–12.1.15.

14.	Hermans, W. T. J. M. C., Brake, O. T., Dijkhuizen, P. A., Sonnemans, M. A. C., Grimm, D., Kleinschmidt, J. A., and Verhaagen, J. (1999) Purification of recombinant adeno-associated virus by iodixanol gradient ultracentrifugation allows rapid and reproducible preparation of vector stocks for gene transfer in the nervous system. Hum. Gene Ther. 10, 1885–1891.

15.	Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY (second edition).

16.	Clark, R. K., Liu, X., McGrath, J. P., and Johnson, P. R. (1999) Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum. Gene Ther. 10, 1031–1039.

17.	Harris, J. D., Schepelmann, S., Athanasopoulos, T., et al. (2002) Inhibition of atherosclerosis in apolipoprotein-E-deficient mice following muscle transduction with adeno-associated virus vectors encoding human apolipoprotein-E. Gene Ther. 9, 21–29.

Comments (Loading...)

Post comment/View all comments